In early May 2004, Epicyte was acquired by Biolex, a protein therapeutics company. Epicyte is a science-based company exploiting Plantibody technology to turn agricultural plants - such as rice and corn - into antibody factories that produce unlimited quantities of pharmaceutical-grade monoclonal antibodies at prices significantly lower than animal cell, culture-based systems.
